人肝细胞癌中瘤周单核细胞的糖酵解激活通过PFKFB3-PD-L1轴促进免疫豁免
研究从肝细胞癌患者外周血、非肿瘤及配对肿瘤组织纯化单核/巨噬细胞,评估其糖酵解转换。发现瘤周单核细胞糖酵解显著增强,通过PFKFB3激活NF-κB上调PD-L1,削弱细胞毒性T淋巴细胞反应;PFKFB3+CD68+细胞浸润与总生存负相关,可作为独立预后因素。
要点
- 瘤周单核细胞糖酵解显著增强并上调PD-L1,抑制肿瘤组织细胞毒性T淋巴细胞反应。
- 肿瘤源性可溶性因子(含透明质酸片段)诱导单核细胞PFKFB3上调,经NF-κB通路上调PD-L1。
- 瘤周组织PFKFB3+CD68+细胞浸润与总生存负相关,可作为肝细胞癌独立预后因素。
核心结论
- 瘤周单核细胞的糖酵解激活通过PFKFB3-PD-L1轴促进免疫豁免,PFKFB3是肝细胞癌潜在治疗靶点。
研究设计与样本
- 从肝细胞癌患者外周血、非肿瘤组织或配对肿瘤组织纯化单核/巨噬细胞,评估糖酵解转换。
- 采用离体分析与体外实验研究代谢转换的调控机制及临床意义。
主要发现
- 瘤周单核细胞糖酵解水平显著增强,糖酵解激活诱导PD-L1表达并减弱肿瘤组织细胞毒性T淋巴细胞反应。
- 肿瘤源性可溶性因子(包括透明质酸片段)诱导肿瘤相关单核细胞中PFKFB3上调。
- PFKFB3通过激活NF-κB信号通路上调PD-L1表达。
- 瘤周组织PFKFB3+CD68+细胞浸润水平与总生存负相关,可作为肝细胞癌独立预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Programmed cell death 1 ligand 1 (PD-L1) expression on antigen-presenting cells is essential for T cell impairment, and PD-L1-expressing macrophages may mechanistically shape and therapeutically predict the clinical efficacy of PD-L1 or programmed cell death 1 blockade. We aimed to elucidate the mechanisms underlying PD-L1 upregulation in human tumor microenvironments, which remain poorly understood despite the clinical success of immune checkpoint inhibitors. METHODS: Monocytes/macrophages were purified from peripheral blood, non-tumor, or paired tumor tissues of patients with hepatocellular carcinoma (HCC), and their possible glycolytic switch was evaluated. The underlying regulatory mechanisms and clinical significance of metabolic switching were studied with both ex vivo analyses and in vitro experiments. RESULTS: We found that monocytes significantly enhanced the levels of glycolysis at the peritumoral region of human HCC. The activation of glycolysis induced PD-L1 expression on these cells and subsequently attenuated cytotoxic T lymphocyte responses in tumor tissues. Mechanistically, tumor-derived soluble factors, including hyaluronan fragments, induced the upregulation of a key glycolytic enzyme, PFKFB3, in tumor-associated monocytes. This enzyme not only modulated the cellular metabolic switch but also mediated the increased expression of PD-L1 by activating the nuclear factor kappa B signaling pathway in these cells. Consistently, the levels of PFKFB3+CD68+ cell infiltration in peritumoral tissues were negatively correlated with overall survival and could serve as an independent prognostic factor for survival in patients with HCC. CONCLUSIONS: Our results reveal a mechanism by which the cellular metabolic switch regulates the pro-tumor functions of monocytes in a specific human tumor microenvironment. PFKFB3 in both cancer cells and tumor-associated monocytes is a potential therapeutic target in human HCC. LAY SUMMARY: Programmed cell death 1 ligand 1 (PD-L1) expressed on antigen-presenting cells, rather than tumor cells, has been reported to play an essential role in checkpoint blockade therapy. A fundamental understanding of mechanisms that regulate the expression of PD-L1 on tumor-infiltrating monocytes/macrophages will undoubtedly lead to the possibility of developing novel PD-L1 blockade strategies with high specificity and efficiency. The current study unveils a novel mechanism by which metabolic switching links immune activation responses to immune tolerance in the tumor milieu, identifying potential targets for future immune-based anti-cancer therapies.
引用
- Chen DP, Ning WR, Jiang ZZ, et al. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. J Hepatol. 2019. PMID: 31071366. doi:10.1016/j.jhep.2019.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。